General Information of Drug (ID: DMNO20J)

Drug Name
mAb926 Drug Info
Indication
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Preclinical [1]
Cross-matching ID
TTD Drug ID
DMNO20J

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
EB8018 DM753H8 Crohn disease DD70 Phase 2 [3]
GSK3882347 DM1DU20 Urinary tract infection GC08 Phase 1 [4]
GSK3882347 DM1DU20 Urinary tract infection GC08 Phase 1 [5]
Biaryl mannoside derivative 24 DMF5TB4 Crohn disease DD70 Patented [6]
PMID26651364-Compound-5 DMH7XL3 Crohn disease DD70 Patented [6]
PMID26651364-Compound-116 DMJ3201 Crohn disease DD70 Patented [6]
Biaryl mannoside derivative 8 DMWF2VG Crohn disease DD70 Patented [6]
Beta-cyclodextrin conjugate derivative 3 DMQJF4P Crohn disease DD70 Patented [6]
PMID26651364-Compound-109 DM01IWV Crohn disease DD70 Patented [6]
PMID26651364-Compound-114 DM5GHJA Crohn disease DD70 Patented [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Fimbrin D-mannose adhesin (Bact FimH) TTTCRU2 FIMH_ECOLI Inhibitor [2]

References

1 Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471.
2 FimH as a scaffold for regulated molecular recognition. J Biol Eng. 2021 Jan 12;15(1):3.
3 Clinical pipeline report, company report or official report of Enterome Biosciences.
4 Clinical pipeline report, company report or official report of Fimbrion Therapeutics
5 Clinical pipeline report, company report or official report of GlaxoSmithKline
6 Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.